GSK (GSK) said Thursday that Japan's Ministry of Health, Labour and Welfare approved a prefilled syringe version of Shingrix for shingles prevention.
The drugmaker said the vaccine was previously supplied in two vials that had to be mixed before use.
The company said the prefilled syringe is ready to use, simplifying administration for healthcare professionals.
GSK launched the prefilled syringe in the US in February 2026 and is rolling it out in Europe throughout this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.